Most cited papers from RenaSci (United Kingdom)

RenaSci (United Kingdom)

What are the most cited papers from RenaSci (United Kingdom)?

The most cited paper from RenaSci (United Kingdom) is "Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents" (Hilary A. Overton, Adam J. Babbs, S. M. Doel et al., 2006), with 656 citations. Next come "Amphetamine, past and present – a pharmacological and clinical perspective" (628) and "GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin" (436).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 12 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Hilary A. Overton, Adam J. Babbs, S. M. Doel et al. · Cell Metabolism Open access	Mar 2006	656
2	Amphetamine, past and present – a pharmacological and clinical perspective David J. Heal, Sharon L. Smith, Jane Gosden et al. · Journal of Psychopharmacology Open access	28 Mar 2013	628
3	GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin Birgitte Holst, Kristoffer Lihme Egerod, Enrico Schild et al. · Endocrinology	7 Sep 2006	436
4	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology Blanca Miriam Bolea-Alamanac, David Nutt, Marios Adamou et al. · Journal of Psychopharmacology	12 Feb 2014	290
5	The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety David J. Heal, Sharon C. Cheetham, Sharon L. Smith · Neuropharmacology	16 Sep 2009	198
6	Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders David J. Heal, Sharon L. Smith, Angels Fisas et al. · Pharmacology & Therapeutics	4 Dec 2007	183
7	Receptor Occupancy and Brain Free Fraction Jeanette M. Watson, S. M. Wright, Adam J. Lucas et al. · Drug Metabolism and Disposition	22 Jan 2009	120
8	Methylphenidate and its Isomers David J. Heal, David M. Pierce · CNS Drugs	2006	117
9	The utility of animal models to evaluate novel anti‐obesity agents Steven P. Vickers, Helen C. Jackson, Sharon C. Cheetham · British Journal of Pharmacology Open access	26 Jan 2011	106
10	New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD David J. Heal, Sharon L. Smith, Rajiv S. Kulkarni et al. · Pharmacology Biochemistry and Behavior	2 Apr 2008	102
11	Chronic 5‐HT 6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese rats Angels Fisas, Xavier Codony, Gonzalo Romero et al. · British Journal of Pharmacology Open access	19 Jun 2006	90
12	Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders David J. Heal, Jane Gosden, Sharon L. Smith · British Journal of Clinical Pharmacology Open access	22 Sep 2009	87
13	Cannabinoids and the Regulation of Ingestive Behaviour Steve P. Vickers, G.A. Kennett · Current Drug Targets	Mar 2005	75
14	Prokineticin 2 Is a Hypothalamic Neuropeptide That Potently Inhibits Food Intake James V. GARDINER, Attia Bataveljic, Neekhil A Patel et al. · Diabetes Open access	23 Nov 2009	67
15	Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Emma L. Lane, Sharon C. Cheetham, Peter G. Jenner · Experimental Neurology	13 Jul 2005	67
16	Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates Matthew J. Hansard, Lance A. Smith, Michael J. Jackson et al. · Journal of Pharmacology and Experimental Therapeutics	2002	66
17	Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats Helen L. Rowley, Rajiv S. Kulkarni, Jane Gosden et al. · Journal of Psychopharmacology Open access	10 Dec 2013	66
18	Serotonin receptor ligands and the treatment of obesity. Steven P. Vickers, Colin Trevor Dourish · PubMed	Apr 2004	66
19	Lisdexamfetamine and immediate release d-amfetamine – Differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity Helen L. Rowley, Rajiv S. Kulkarni, Jane Gosden et al. · Neuropharmacology	14 Jul 2012	65
20	The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats Matthew John Fell, N. Anjum, Keith Dickinson et al. · Psychopharmacology	20 Jun 2007	63
21	What is the prognosis for new centrally-acting anti-obesity drugs? David J. Heal, Jane Gosden, Sharon L. Smith · Neuropharmacology	30 Jan 2012	63
22	Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet Steven P. Vickers, Sharon C. Cheetham, Katie R. Headland et al. · Diabetes Metabolic Syndrome and Obesity Open access	Jul 2014	63
23	Effects of lisdexamfetamine in a rat model of binge-eating Steven P. Vickers, David P. Hackett, Fraser Murray et al. · Journal of Psychopharmacology	20 Nov 2015	58
24	ADHD: Current and Future Therapeutics David J. Heal, Sharon L. Smith, Robert L. Findling · Current topics in behavioral neurosciences Book chapter	2011	54
25	A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil David J. Heal, Niki Buckley, Jane Gosden et al. · Neuropharmacology	6 Jun 2013	51
26	Dopamine reuptake transporter (DAT) “inverse agonism” – A novel hypothesis to explain the enigmatic pharmacology of cocaine David J. Heal, Jane Gosden, Sharon L. Smith · Neuropharmacology	19 Jun 2014	51
27	Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β‐cell mass in a streptozotocin‐induced mouse model of type 2 diabetes Simon M. Poucher, Sharon C. Cheetham, J. Francis et al. · Diabetes Obesity and Metabolism	8 May 2012	50
28	Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans David J. Heal, Jane Gosden, Sharon L. Smith · Neuropharmacology	8 Feb 2018	49
29	Characterisation of Pain Responses in the High Fat Diet/Streptozotocin Model of Diabetes and the Analgesic Effects of Antidiabetic Treatments Frederika Byrne, Sharon C. Cheetham, Steven P. Vickers et al. · Journal of Diabetes Research Open access	2015	48
30	Investigation of impulsivity in binge-eating rats in a delay-discounting task and its prevention by the d-amphetamine prodrug, lisdexamfetamine Steven P. Vickers, Simon Goddard, Richard J Brammer et al. · Journal of Psychopharmacology	Feb 2017	39
31	Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice C. Daniel Moser, Steve P. Vickers, Richard J Brammer et al. · Phytomedicine	8 Jul 2014	39
32	Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo Nimish Sidhpura, Peter H. Redfern, Helen L. Rowley et al. · Biochemical Pharmacology	22 Jun 2007	38
33	Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice Katharine Pillidge, Ashley J. Porter, Temis Vasili et al. · Pharmacology Biochemistry and Behavior Open access	24 Oct 2014	37
34	A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo Orla Galvin, Akshay Kumar Srivastava, Oliver Carroll et al. · Journal of Controlled Release Open access	13 Apr 2016	36
35	KTX 0101: A Potential Metabolic Approach to Cytoprotection in Major Surgery and Neurological Disorders Sharon L. Smith, David J. Heal, Keith F. Martin · CNS Drug Reviews Open access	Mar 2005	36
36	Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity David J. Heal, Jane Gosden, Helen C. Jackson et al. · Handbook of experimental pharmacology Book chapter	2012	32
37	Sex differences in auditory fear discrimination are associated with altered medial prefrontal cortex function Harriet L. L. Day, Sopapun Suwansawang, David M. Halliday et al. · Scientific Reports Open access	14 Apr 2020	31
38	Lisdexamfetamine reduces the compulsive and perseverative behaviour of binge-eating rats in a novel food reward/punished responding conflict model David J. Heal, Simon Goddard, Richard J Brammer et al. · Journal of Psychopharmacology Open access	11 May 2016	30
39	A comparison of the effects of the CB1 receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour Zoë D. Thornton-Jones, G.A. Kennett, Steven P. Vickers et al. · Psychopharmacology Open access	19 Mar 2007	30
40	The 5-HT6 Receptor as a Target for Developing Novel Antiobesity Drugs David J. Heal, Jane Gosden, Sharon L. Smith · International review of neurobiology Book chapter	2011	30
41	Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity in Vivo Mouse Model Christophe Fromont et al. · Journal of Medicinal Chemistry Open access	20 May 2020	28
42	Dopamine and μ-opioid receptor dysregulation in the brains of binge-eating female rats – possible relevance in the psychopathology and treatment of binge-eating disorder David J. Heal, Michelle Hallam, Michael R. Prow et al. · Journal of Psychopharmacology	5 Apr 2017	28
43	Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates Matthew J. Hansard, Lance A. Smith, Michael J Jackson et al. · European Journal of Pharmacology	Sep 2002	28
44	Inhibition of alpha7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine‐conditioned place preference and associated changes in AMPA receptor binding Victoria Wright, Polymnia Georgiou, Alexis Bailey et al. · Addiction Biology Open access	17 Apr 2018	27
45	A review of late-stage CNS drug candidates for the treatment of obesity David J. Heal, Jane Gosden, Sharon L. Smith · International Journal of Obesity	13 Mar 2012	24
46	Catecholamines: Knowledge and understanding in the 1960s, now, and in the future S. Clare Stanford, David J. Heal · Brain and Neuroscience Advances Open access	2019	23
47	Pharmacological characterisation of the thermogenic effect of bupropion Yong-Ling Liu, Ian P. Connoley, David J. Heal et al. · European Journal of Pharmacology	14 Aug 2004	23
48	The behavioural response of mice lacking NK1 receptors to guanfacine resembles its clinical profile in treatment of ADHD Katharine Pillidge, Ashley J. Porter, Julia A. Dudley et al. · British Journal of Pharmacology Open access	29 Jul 2014	22
49	The Beta-adrenergic agonist, Ractopamine, increases skeletal muscle expression of Asparagine Synthetase as part of an integrated stress response gene program David M. Brown, Kevin J. Ryan, Zoe C. T. R. Daniel et al. · Scientific Reports Open access	23 Oct 2018	21
50	Novel targets for the treatment of obesity: a review of progress Sharon C. Cheetham, Helen C. Jackson, Steven P. Vickers et al. · Drug Discovery Today Therapeutic Strategies	Oct 2004	21

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.